Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions.

What is 'chronic' pustular psoriasis? Identifying candidates for long-term subcutaneous spesolimab treatment.

Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis).

Lipid-Lowering Therapy and Cardiovascular Prevention in Elderly.

Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis).

Occlusion of the false lumen, management of aortic side branches.

Using Biologics to Reduce Long-Term Corticosteroid Use in Pyoderma Gangrenosum: Real-World Evidence From Two Centres.

Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience.

Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis).

Age of Onset Matters: Tildrakizumab Response in Early vs Late-Onset Psoriasis.